Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00541190 · ClinicalTrials.gov registry record · NA

Absorptive Clearance in the Cystic Fibrosis Airway

A NA study of Cystic Fibrosis, sponsored by University of Pittsburgh.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT00541190: Completed NA study of Cystic Fibrosis, sponsored by University of Pittsburgh.

NCT00541190 is a NA study of Cystic Fibrosis that has completed, run by University of Pittsburgh. The registered enrollment target is 21 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00541190, a NA study of Cystic Fibrosis, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The objective of this overall project is to develop a new aerosol-based technique for quantifying liquid absorption in the airways of subjects with cystic fibrosis(CF) that can be used to help develop new therapies. In CF, mutations in the CF gene result in dysfunction of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ion channel on the cells that line the airway epithelium, causing improper fluxes of ions such as sodium, chloride, and bicarbonate. The so called "low volume" hypothesis of CF pathogenesis contends that abnormal absorption of ions from the airways causes excessive absorption of liquid, resulting in an airway surface liquid layer that is dehydrated and difficult to clear. Here we are measuring the absorption rate of a radiolabeled small molecule (DTPA) from the lungs of cystic fibrosis patients and healthy controls. We hypothesize that the molecule will absorb more quickly in cystic fibrosis patients. Further studies will be performed to determine if DTPA absorption is related to liquid absorption in the airways.

Primary Outcome

The absorptive clearance rate is the percentage of the radiolabeled small molecule DTPA that is cleared through absorption over a 60 minute period. Total DTPA clearance includes absorptive and mucociliary components. The mucociliary component is determined by measuring the clearance of a radiolabeled particle over the same period (Technetium 99m sulfur colloid; Tc-SC), and subtracted from total DTPA clearance in order to determine the absorptive component. Here we specifically report absorption

Conditions Studied

Interventions

  • OTHER Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2007-10
Est. Completion 2008-04
Phase NA
University of Pittsburgh

1,238 total trials

What the finished NCT00541190 record still lists

NCT00541190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA is the first listed.

NCT00541190 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00541190 about?

NCT00541190 is a clinical study titled "Absorptive Clearance in the Cystic Fibrosis Airway". The objective of this overall project is to develop a new aerosol-based technique for quantifying liquid absorption in the airways of subjects with cystic fibrosis(CF) that can be used to help develop new therapies. In CF, mutations in the CF gene result in dysfunction of the Cystic Fibrosis Transme...

What is the current status of trial NCT00541190?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2007-10. Estimated completion is 2008-04.

What conditions does trial NCT00541190 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT00541190?

The interventions under investigation include: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA (OTHER).

Who is sponsoring clinical trial NCT00541190?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00541190 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00541190's enrollment target sits among peer trials

21 127th of 169 higher than 41 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00541190, the US trial registry maintained by the National Library of Medicine. NCT00541190 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.